AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35617162 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall motion score index
Number of subjects: 136
Study 35617162 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 136
Study 35617162 — intervention group
Group type: COMPARATOR
Intervention: Barthel's score
Number of subjects: 136
Study 35617162 — intervention group
Group type: COMPARATOR
Intervention: Karnofsky score
Number of subjects: 136
Study 35617288 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sequelae assessment (physical, neurological, or sensory)
Number of subjects: 100
Study 35617288 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term post-traumatic stress assessment in parents
Number of subjects: 100
Study 35617367 — intervention group
Group type: EXPERIMENTAL
Intervention: TsG10-TsG10-*bt assay
Number of subjects: 29
Study 35617367 — intervention group
Group type: COMPARATOR
Intervention: Polyclonal based assay
Number of subjects: 29
Study 35617367 — intervention group
Group type: EXPERIMENTAL
Intervention: New recombinant monoclonal antibody-based Ts Ag detection immunoassay
Number of subjects: 29
Study 35617367 — intervention group
Group type: EXPERIMENTAL
Intervention: TsG10 assay
Number of subjects: 29
Study 35617367 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Ts antigen in urine
Number of subjects: 29
Study 35617646 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) enumeration and expression of HLA I and PD-L1
Number of subjects: 104
Study 35617646 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC enumeration trajectory in the highest quartile (> 0.12 CTCs/mL annually)
Number of subjects: 104
Study 35617646 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC enumeration and HP ratio changes over time
Number of subjects: 104
Study 35617923 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35617978 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation segmentectomy
Number of subjects: 29
Study 35618285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) intravenously every 21 days
Number of subjects: 29
Study 35618347 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 412
Study 35618353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin measurement
Number of subjects: 0
Study 35618353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35618441 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (5, 10, or 20 mg/kg every other week for 6 months, then 20 mg/kg qow)
Number of subjects: 24
Study 35618441 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa
Number of subjects: 24
Study 35619114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake during pregnancy
Number of subjects: 458
Study 35619134 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1888
Study 35619134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels (two-fold increase)
Number of subjects: 1888
Study 35619189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized haMSC-Exos (2.0 × 10^6 exosomes daily for 5 days)
Number of subjects: 7
Study 35619542 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care support
Number of subjects: 196
Study 35619542 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends/family support
Number of subjects: 196
Study 35619611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation (TTEN) for 4 weeks, daily 20 min sessions
Number of subjects: 12
Study 35619611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation (TTEN)
Number of subjects: 12
Study 35620522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (500 mg, 2×/day)
Number of subjects: 94
Study 35620522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 35621203 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure quartiles in early 40s
Number of subjects: 2591
Study 35621203 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analyses
Number of subjects: 2591
Study 35622006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for Hirschsprung disease (HD)
Number of subjects: 0
Study 35622006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of hospitalization for HD
Number of subjects: 0
Study 35622006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-through procedures in neonatal age group
Number of subjects: 0
Study 35622006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality rate for HD
Number of subjects: 0
Study 35622006 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) for HD hospitalization
Number of subjects: 0
Study 35622074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody) combined with hyper-CVAD regimen
Number of subjects: 0
Study 35622074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (anti-CD20 monoclonal antibody)
Number of subjects: 0
Study 35622074 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 35622074 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (anti-CD22 monoclonal antibody)
Number of subjects: 0
Study 35622082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme medication (Creon)
Number of subjects: 11
Study 35622315 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W)
Number of subjects: 22
Study 35622394 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital behavior change intervention combining PSD principles and BCTs
Number of subjects: 45
Study 35622394 — intervention group
Group type: EXPERIMENTAL
Intervention: Week Plan, My Overview, Knowledge and Skills, Virtual Coach and Smart Feedback System
Number of subjects: 45
Study 35622394 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of PSD principles such as tailoring, personalization, self-monitoring, reminders, rewards, rehearsal, praise, and suggestions
Number of subjects: 45
Study 35622394 — intervention group
Group type: EXPERIMENTAL
Intervention: BCTs from clusters of goals and planning, feedback and monitoring, social support, repetition and substitution, shaping knowledge, natural consequences, associations, antecedents, identity, and self-belief
Number of subjects: 45
Study 35622434 — intervention group
Group type: EXPERIMENTAL
Intervention: GI involvement in hospitalized children with acute COVID-19 or MIS-C
Number of subjects: 789
Study 35622434 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-C patients with GI involvement
Number of subjects: 789
Study 35622535 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol ocular ointment
Number of subjects: 527
Study 35622535 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid ocular gels
Number of subjects: 527
Study 35622535 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol-clotrimazole
Number of subjects: 527
Study 35622535 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol-placebo
Number of subjects: 527
Study 35623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 35623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 35623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0
Study 35623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study 35623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (PD-L1, MSI-H, EBV, TMB)
Number of subjects: 0
Study 35623341 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 regimens targeting diverse biology
Number of subjects: 990
Study 35623341 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassification and improved patient selection
Number of subjects: 990
Study 35623759 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer eSupport (internet-based intervention)
Number of subjects: 0
Study 35623833 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weeks-567-kcal-hospital-controlled-VLCD
Number of subjects: 22
Study 35623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold thickness (SFT)
Number of subjects: 181
Study 35623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 181
Study 35623838 — intervention group
Group type: COMPARATOR
Intervention: Pre-pregnancy body mass index (pBMI)
Number of subjects: 181
Study 35623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 181
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (SF < 15.0 μg/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron insufficiency (SF < 20.0 μg/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron insufficiency (SF < 25.0 μg/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA) (Hb < 12.0 g/dL and SF < 15.0 μg/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (Hb < 12.0 g/dL)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 8.0 g/dL)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP > 5.0 mg/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 acid glycoprotein (AGP > 1.0 g/L)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency (rural vs. urban)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of iron insufficiency (rural vs. urban)
Number of subjects: 979
Study 35623855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency anemia (IDA) (rural vs. urban)
Number of subjects: 979
Study 35623864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education + Refined white sugar
Number of subjects: 105
Study 35623864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education + Minimally Refined Brown Sugar
Number of subjects: 105
Study 35623864 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 105
Study 35623976 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and therapy guides
Number of subjects: 132
Study 35624056 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of VTS-Aspirin and ketamine (mean ketamine dose 37.8 mg, range 24 mg to 50 mg)
Number of subjects: 25
Study 35624056 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of VTS-Aspirin and ketamine
Number of subjects: 25
Study 35624401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral neuromuscular electrical stimulation (NMES) device
Number of subjects: 65
Study 35624405 — intervention group
Group type: EXPERIMENTAL
Intervention: Micrographia writing test in PD patients
Number of subjects: 226
Study 35624405 — intervention group
Group type: COMPARATOR
Intervention: Micrographia writing test in ET patients
Number of subjects: 226
Study 35624405 — intervention group
Group type: COMPARATOR
Intervention: Micrographia writing test in healthy controls
Number of subjects: 226
Study 35624418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at a dose of 0.5 μg/kg, adjusted in 0.1 μg/kg gradients based on previous patient outcomes.
Number of subjects: 20
Study 35624418 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (not specified in the trial but mentioned as a comparison).
Number of subjects: 20
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Helsinki Declaration on Patient Safety in Anesthesiology
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of work with application of the Helsinki Declaration
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory perioperative monitoring
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clinical protocols for massive bleeding
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clinical protocols for infection control
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the WHO Safe Surgery checklist
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of checklists for equipment inspection
Number of subjects: 210
Study 35624436 — intervention group
Group type: EXPERIMENTAL
Intervention: Record keeping of anesthesia complications
Number of subjects: 210
Study 35624438 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 35624438 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and its risk gene polymorphism
Number of subjects: 0
Study 35624438 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes and environment interaction
Number of subjects: 0
Study 35624438 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of precocious puberty
Number of subjects: 0
Study 35624443 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic decompression
Number of subjects: 600
Study 35624443 — intervention group
Group type: COMPARATOR
Intervention: Open decompression and fusion
Number of subjects: 600
Study 35624489 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 10
Study 35625006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (4 weeks/18 weeks)
Number of subjects: 0
Study 35625006 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurorehabilitation alone (22 weeks)
Number of subjects: 0
Study 35625330 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS, accelerated Q-SRP within 24 h)
Number of subjects: 105
Study 35625330 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling with chlorhexidine-based disinfection (FMD)
Number of subjects: 105
Study 35625330 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD with adjuvant erythritol air polishing (FMDAP)
Number of subjects: 105
Study 35625330 — intervention group
Group type: COMPARATOR
Intervention: Quadrant/week-wise debridement (Q-SRP)
Number of subjects: 105
Study 35626701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human immature dental pulp stem cells (hIDPSC)
Number of subjects: 0
Study 35626772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute physical activity (PA)
Number of subjects: 0
Study 35626772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic physical activity (PA)
Number of subjects: 0
Study 35626772 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35627467 — intervention group
Group type: EXPERIMENTAL
Intervention: Three co-wear criteria of varying stringency
Number of subjects: 0
Study 35627709 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-paroxysmal AF
Number of subjects: 2160
Study 35627709 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 2160
Study 35627709 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oral anticoagulants
Number of subjects: 2160
Study 35627709 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antiarrhythmic and diuretic agents
Number of subjects: 2160
Study 35627958 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for three months
Number of subjects: 0
Study 35627958 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training for three months
Number of subjects: 0
Study 35627958 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles (EVs) from people with diabetes
Number of subjects: 30
Study 35628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic and phosphoproteomic analysis of EVs
Number of subjects: 30
Study 35628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphosite-centric analyses using directPA and PhosR software
Number of subjects: 30
Study 35628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-specific markers in EVs
Number of subjects: 30
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic OAC (various types including rivaroxaban, dabigatran, apixaban, and vitamin K antagonists)
Number of subjects: 3109
Study 35628832 — intervention group
Group type: COMPARATOR
Intervention: No OAC
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VKA OACs (NOACs)
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 3109
Study 35628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic OAC (general)
Number of subjects: 3109
Study 35628896 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH) at FiO2 15% (≈ 2500 m simulated altitude)
Number of subjects: 21
Study 35628896 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH) at 2500 m
Number of subjects: 21
Study 35628896 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 21
Study 35628955 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 15
Study 35629011 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated proteomic biomarker risk predictor
Number of subjects: 0
Study 35629011 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound dating
Number of subjects: 0
Study 35629011 — intervention group
Group type: COMPARATOR
Intervention: Excluding dating by LMP
Number of subjects: 0
Study 35629127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen pulse measurement
Number of subjects: 0
Study 35629127 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 35629401 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic atherosclerosis
Number of subjects: 509
Study 35632416 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 1 year after primary immunization (Group 1)
Number of subjects: 849
Study 35632416 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 2 years after primary immunization (Group 2)
Number of subjects: 849
Study 35632416 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 3 years after primary immunization (Group 3)
Number of subjects: 849
Study 35632821 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 0
Study 35633291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-detected hypoglycaemia (SDH) using continuous glucose monitoring (CGM) for 10 weeks
Number of subjects: 600
Study 35633291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment via mobile app
Number of subjects: 600
Study 35633291 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic outcomes assessment
Number of subjects: 600
Study 35633435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling Attitudes and Beliefs Survey (GABS)
Number of subjects: 415
Study 35633435 — intervention group
Group type: EXPERIMENTAL
Intervention: GABS
Number of subjects: 415
Study 35633970 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of autologous thymic-derived regulatory T cells (thyTreg)
Number of subjects: 0
Study 35633970 — intervention group
Group type: COMPARATOR
Intervention: Chronic immunosuppression
Number of subjects: 0
Study 35634171 — intervention group
Group type: EXPERIMENTAL
Intervention: IC/IR820 NPs
Number of subjects: 0
Study 35634171 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 35634171 — intervention group
Group type: EXPERIMENTAL
Intervention: Photothermal therapy
Number of subjects: 0
Study 35634208 — intervention group
Group type: EXPERIMENTAL
Intervention: MST + sham tDCS
Number of subjects: 26
Study 35634208 — intervention group
Group type: COMPARATOR
Intervention: MST + tDCS
Number of subjects: 26
Study 35634390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed macronutrient tolerance test (MMTT) containing 56-g palm oil, 59-g sucrose, and 26-g egg white protein
Number of subjects: 0
Study 35634417 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of a dietary multi-ingredient nootropic
Number of subjects: 26
Study 35634417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 35634506 — intervention group
Group type: COMPARATOR
Intervention: Irisin serum levels in CMT patients (6.51 ± 2.26 μg/ml)
Number of subjects: 20
Study 35634506 — intervention group
Group type: COMPARATOR
Intervention: Irisin serum levels in CMT patients with pathological muscle strength (5.56 ± 1.26 μg/ml)
Number of subjects: 20
Study 35634506 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of irisin with P1PN
Number of subjects: 20
Study 35634506 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of irisin with Vitamin D
Number of subjects: 20
Study 35634506 — intervention group
Group type: EXPERIMENTAL
Intervention: Irisin levels in women (7.31 ± 2.53 μg/ml)
Number of subjects: 20
Study 35634506 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of irisin with muscle strength in women
Number of subjects: 20
Study 35634506 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of irisin with muscle quality in women
Number of subjects: 20
Study 35635160 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 1406